USPI Highlights: A Guide to FDA Drug Labeling Requirements

The Prescribing Information (USPI) and the Emergence of “Highlights”

A US prescription drug’s label includes the Prescribing Information (PI), a detailed document for healthcare professionals. The PI is the FDA’s “primary tool for communicating a summary of the essential scientific information needed for the safe and effective use of the drug” (^[10]). In 2006, to improve the usability of drug labels for busy clinicians, the FDA implemented a major overhaul: the Physician Labeling Rule (PLR). This rule, codified at 21 CFR 201.56–201.57, reorganized labels into a standard format and introduced the Highlights of Prescribing Information, a concise summary section at the very beginning (^[11]) (^[1]). Prior to this, labels were long, non-standardized texts; the PLR aimed to create a clear “executive summary” of the key points, recognizing that prescribers have limited time and need quick access to crucial facts (^[1]) (^[10]).

The Highlights section was expressly designed to “summarize the most important information about benefits and risks” (^[12]). It typically appears as one or two pages of boxed warnings, bullet points, and brief paragraphs. The FDA guidance emphasizes that Highlights should be “concise” and targeted – every element (the drug’s name, indication, dosage, etc.) is chosen to give providers a rapid yet balanced understanding of how and when to use the drug safely (^[2]) (^[13]). Since the PLR took effect, the requirements in 21 CFR 201.57 apply to the prescription drug products described in 21 CFR 201.56(b)(1); other prescription-drug labeling may be subject to different requirements. Today, over 155,000 drug labels on the FDA’s Labeling Resources (e.g., DailyMed) use PLR – each with a Highlights page (^[14]) (^[2]). The FDA’s FDALabel full-text search tool, maintained by the National Center for Toxicological Research, now enables customizable searches across this entire corpus and is updated twice monthly with new labels from manufacturers (^[15]).

Because Highlights is at the front of the label, it carries significant weight: prescribers will often read it first or even exclusively. Thus, optimizing Highlights is vital. It must be legally compliant (including required verbatim statements and risk disclosures (^[16]) (^[17])) and clinically useful (presenting indications, dosages, and common adverse effects in digestible form). At the same time, pharmaceutical companies want to ensure the drug’s value proposition – its compelling advantages over existing therapies – is clearly communicated. However, the FDA explicitly forbids promotional or misleading language in labeling (^[4]) (^[6]). In practice, this means that Highlights must present the approved indication and other required information concisely, accurately, and without promotional framing; all claims must be supported by the approved labeling (^[3]) (^[18]).

This report explores how to achieve that balance. We begin by detailing the regulatory requirements for Highlights (drawing on the U.S. Code of Federal Regulations and FDA guidance (^[17]) (^[19])). We then examine drafting practices for clarity, including how to state approved indications, structure required information, and present clinically significant safety information without minimizing it. We incorporate insights from academic research on how physicians use PIs (^[8]), from pharmaceutical labeling experts (^[3]) (^[7]), and from real examples of effective Highlights (^[9]). Through regulatory analysis, case studies, and future outlook, this guide explains how to prepare Highlights that satisfy FDA requirements and support clear access to approved prescribing information.

The content and format of Highlights are governed by 21 CFR 201.57(a). Table 1 distinguishes required structural statements from content that is required only when applicable to a product.

Table 1: Required elements of the Highlights section (21 CFR 201.57(a)), with regulatory source and purpose. Citations reference the regulatory text and FDA guidance.

The required Highlights structure is set by regulation, but several entries are conditional or product-specific—for example, a Boxed Warning appears only when applicable, and safety summaries depend on the approved product information. For example, 21 CFR 201.57(a)(1) mandates the exact text of the Highlights Limitation Statement (^[17]). Omitting or changing this verbatim warning is a direct violation (^[20]). Likewise, the Boxed Warning must appear first (when present), in bold and bordered, with the heading “WARNING” (^[44]) (^[45]). The list above derives from the Code of Federal Regulations, which we cite extensively (^[17]) (^[38]).

Beyond listing required elements, the regulation sets the applicable format and length standard: Highlights content, excluding any boxed warning, must fit on one-half of a page under the specified two-column, single-spaced, 8-point-type, ½-inch-margin conditions. The regulation also requires a minimum 8-point type size for the specified labeling information. Cross-references in Highlights should hyperlink to the detailed sections of the full PI (e.g. references such as “(See 1.1)” that point to Section 1.1) (^[46]). The Highlights must also include administrative metadata like the Initial U.S. Approval year and Revision Date (^[47]) (^[48]). As the FDA FAQ explains, items like the “Established pharmacologic class” of the drug and a postmarketing adverse event reporting statement are typical features in Highlights (^[49]) (^[50]).

Notably, the law does not allow marketing-style embellishments. Any statement comparing the drug’s safety or efficacy to other products greater or less must be backed by substantial evidence (^[18]). Thus, superlative claims (“best-in-class”, “unmatched efficacy”) are prohibited unless explicitly supported by data and FDA-approved.

In summary, Highlights is a carefully structured, legally defined summary of approved prescribing information. It is not promotional material. Drafting should faithfully and concisely present the required information, including clinically significant safety information, in the required format.

Beyond regulatory compliance, effective Highlights writing requires clarity, brevity, and reader-friendly formatting. It must communicate complex information precisely in a busy clinical environment. Based on FDA guidance, literature, and industry recommendations, we outline key best practices:

• Conciseness and bullets. Because Highlights is an “A-to-Z” snapshot, use short sentences and bullet points wherever possible. Complex sentences should be split. Summaries (“Concise summary of indications...”, “Concise summary of the most common adverse reactions...”) are emphasized in the regulation (^[51]) (^[36]). In practice, each section (Indications, Dosage, etc.) is often formatted as a bulleted list of key facts. For example, Invokana’s Highlights uses bullets for each indication (^[9]), and for each dosing recommendation (^[52]). Bullets make scanning easy and draw attention to each point.

• Balance and neutrality. The Highlights must present benefits and risks in equal measure (^[3]). FDA explicitly notes, “Balance is key. The FDA will not let you list all your indications if you don’t also list your most serious warnings” (^[3]). In other words, one cannot emphasize an indication without also including relevant boxed warnings or contraindications. Furthermore, label text must not be promotional or misleading (^[4]) (^[6]). Avoid superlatives (e.g. “best”, “first and only”) and unsupported claims (“improves adherence”). The key value statements should be factual (evidence-based) and tempered with appropriate risk information. CRAS training bluntly warns against a “promotional tone” (^[3]) (^[6]).

• Clarity and specificity. Physicians value explicit language. A recent study of U.S. doctors found they strongly prefer explicitly stating age groups in Indications (e.g. “adults” or “10 years and older”) even when the disease is typically age-specific (^[8]). Similarly, they want dosage instructions to clearly mention food requirements (“take with or without food”) (^[8]). The takeaway: do not rely on assumed context. Always specify the patient group and administration details in plain terms. One example: in a test of hypothetical wording, physicians interpreted “indicated for treatment of adults with disease X” differently than a terse “indicated for disease X.” Including “adults” avoided confusion whether pediatrics were included (^[8]).

• Organized format. The Highlights should flow in the logical order given by 21 CFR: Warning (if any), Recent Changes, Indications, Dosage, Forms, Contraindications, Warnings/Precautions, Adverse Reactions, Interactions, Specific Populations, Counseling, Revision date (^[20]) (^[25]). Within each section, group related points. For instance, under Dosage and Administration, separate points for starting dose, dose titration, and adjustments for renal impairment as needed (^[30]). Adverse Reactions are often presented as a bullet list of the most common events (usually ≥5% incidence) (^[36]) (^[37]). Using sub-bullets for closely related notes (e.g. under Warnings, list each risk as a separate bullet) improves readability.

• Formatting consistency. Follow strict style conventions. Use a two-column layout and legible fonts (FDA specifies ≥8-point; typically 9- or 10-point is used) (^[53]). Boldface and boxing highlight the Warning header (^[25]). Ensure consistent units (“mg” vs “mg/mL”), drug naming (use the approved generic name), and terminology (e.g. “contraindicated” vs “avoid use” – see below) throughout. All cross-references (e.g. “(see 5.2)”) should be accurate to avoid confusion.

• Risk section organization. Within Warnings and Precautions, prioritize the most clinically critical items (typically 5–7 largest or most dangerous risks) (^[35]). One consensus approach is to word warnings in logical order: list the adverse event first (what can happen), followed by risk factors and management steps (^[54]). This was preferred by physicians in cognitive testing (^[54]). For example, a warning bullet could be: “Hepatotoxicity: [Drug] can cause liver injury (see 5.1). Monitor ALT before starting and periodically. Discontinue if ALT >3×ULN.” Grouped information like this helps situational awareness. For Adverse Reactions, some experts recommend small tables or organized lists by frequency, mirroring clinical study presentations (^[55]).

• Terminology consistency. Establish a terms glossary (endpoints, abbreviations, etc.) consistent with the clinical trial publications (CSR) and prior labeling. Avoid synonyms and promotional synonyms. For example, instead of calling a benefit “profound,” simply state “X% reduction in LDL achieved” (if allowed, see discussion on endpoints below). [Be careful: any numeric claim must match what’s in the approved labelling].

• Use of cross-references. Because Highlights is a summary, every statement usually points to the detailed section in the full PI (^[46]). For example, a boxed warning line might read “(5.1)” immediately after. In electronic label (SPL XML), these become hyperlinks. This reassures the reader that the summary is anchored in the full data (^[46]).

• Avoid over-listing in interactions. Interesting finding from physician interviews: too many examples of interacting drugs in highlights may be counterproductive. A long list of drug names can falsely imply that only those listed are relevant, potentially giving a false sense of completeness (^[8]). The preferred pattern is a concise class-based statement (e.g. “Strong CYP3A4 inhibitors: avoid use”) without enumerating every drug unless absolutely necessary. If examples are helpful, give just a few representative ones, not an exhaustive list (^[8]).

In summary, unclear or unnecessarily complex wording is the enemy. Highlights should be written plainly, precisely, and with healthcare professionals’ information needs in mind. The language must be accurate and evidence-based (^[4]), but also patient-centered in the sense of being easy for a doctor to action. The next section addresses how to draft each Highlights component from the approved labeling.

The purpose of drafting Highlights is to summarize the approved indication, dosing, and clinically significant safety information accurately and concisely. It is not a vehicle for promotional differentiation. The FDA reviews Prescribing Information to ensure that it is informative and accurate and neither promotional in tone nor false or misleading. (^[56])

The Indications and Usage section is the most important opportunity to state Why this drug matters. Under 21 CFR, it must state the FDA-approved indication(s) in concise form (^[27]). Within that tight wording, companies can underscore clinical benefits. Key tactics include:

• Precise disease keywords. Use clinical terms that resonate (e.g. “reduce morbidity,” “improve survival,” “improve glycemic control”). For example, Invokana’s Highlights say: “adjunct to diet and exercise to improve glycemic control in adults… with type 2 diabetes” (^[9]). The phrase “improve glycemic control” encapsulates the drug’s core effect. Notice it doesn’t just say “treatment of type 2 diabetes mellitus” – it explicitly says what positive goal is achieved. Similarly, oncology drugs often specify “for the treatment of [cancer] to interrupt disease progression” rather than a generic label. Whenever possible, include the expected clinical outcome directly.

• Multiple indications as bullets. If a drug has more than one indication, bullet each one. This allows each benefit to stand out. In Invokana’s Highlights, each indication is a separate bullet: glycemic control, cardiovascular risk reduction, and renal protection (^[9]). This format immediately shows a broad value proposition (glucose lowering and cardio/kidney protection). For a drug with one main indication plus an adjunctive one (e.g. “X is indicated to treat A; also for B”), consider separate sub-bullets or semibolding to differentiate them.

• EPC (Established Pharmacologic Class). FDA guidance encourages listing the “pharmacologic class” in the Indications heading (^[57]). This can underscore a novelty or advantage. For instance, if a drug is the first in a new class (e.g. “First-in-class once-weekly GLP-1 receptor agonist”), the class label “GLP-1 receptor agonist” signals where it fits in therapy. Even if not first-in-class, stating the class reminds clinicians of known effects or contrasts (“androgen for bulls” examples in guidance). When applicable, Highlights must identify the established pharmacologic class.

• Quantitative endpoints (with caution). The Highlights wording typically does not quote study data (those belong to Section 14 “Clinical Studies”). However, if an indication was granted based on a particular endpoint (e.g. a percentage reduction in an outcome), one can briefly allude to it in text. For example, a label might read “to improve progression-free survival in metastatic cancer, based on trial evidence (see Trial sections)”. One must be careful: any numeric claim or comparative statement must be exactly supported by approved labeling data (^[18]). In practice, many Highlights avoid raw numbers, focusing instead on the indication itself.

• Explicit limitations. To build credibility, also state any key limits of use. For instance, if the drug is only for adults or not for refractory cases, that should be noted (as Invokana’s “Not recommended...” lines do (^[58])). Limitations can highlight a niche value – e.g. “reserved for patients with failure of standard therapy” signals it’s a second-line agent. Transparency here reinforces trust.

• Strategic phrasing. Use positive, active language. Instead of passive or medical-ese, say “X treats disease Y” or “X reduces X by Y” (if allowed by labeling). Avoid downplaying words like “indicated for the use of X” (wordy and passive) when not required. The PLR allows a complete sentence under Indications. E.g. “DrugX is a [class] indicated for [treatment of condition]” (^[57]). This format (subject-verb-indication) is clear and affirmative.

Example (current label): INVOKANA (canagliflozin) is an SGLT2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Its cardiovascular and kidney-outcome indications remain limited to defined adult populations. The separate indication bullets state these distinct approved uses concisely without promotional claims. (^[59])

In short, use the FDA-approved indication language accurately and concisely. Every clause in the Indications and Usage summary should reflect the approved use, population, limitations, and any outcome claim already present in the approved label.

The Dosage and Administration summary provides the approved information clinicians need to use the drug. It should present the applicable regimen and critical administration instructions accurately and concisely, without implying convenience, broader applicability, or an advantage over other therapies:

• Clarity on dosing regimen. State the default dose succinctly. If a drug has a simple regimen (e.g. “100 mg once daily”), that is itself a benefit compared to a thrice-daily competitor. For instance, Invokana’s highlights say: “The recommended starting dosage in... is 100 mg orally once daily, taken before the first meal…” (^[60]). This not only gives the dose but highlights “once daily” and “before the first meal to improve glycemic control”. Here, “before first meal” cues the Efficacy rationale (glucose rise after breakfast).

• Special population pointers. If certain groups benefit or need dose changes, mention them. For example, saying “starting dose in renal impairment is adjusted” or “no dosage change needed in elderly” can be part of the narrative. This assures prescribers of safe use, e.g. “No dose adjustment is needed for patients ≥65 years” if true. Conversely, highlighting an easy regimen (“no titration needed”) is a plus.

• Monitoring or pretreatment steps. FDA often expects “obtain baseline X” in section 2 if required. Phrasing these as recommendations (e.g. “Assess thyroid function prior to starting” or “Monitor serum electrolytes periodically”) shows responsibility. In a value context, it shows the drug comes with clear safety measures. If relevant, note conveniences: for example “can be taken with or without food” (this sort of thing was explicitly preferred by physicians (^[8])).

• Avoid clutter. Only the most critical dosage instructions appear in Highlights. Do not try to list every titration scheme – that belongs in the full label. Focus on starting dose, route, major adjustment, and mention “see full PI for details” if necessary. The point is to give prescribers a quick dosing blueprint.

• Scope of the summary. Include only the critical dosage and administration information required for safe and effective use and supported by the approved labeling. Do not use dosing, monitoring, age, weight, or renal-function statements to imply convenience, broader applicability, or another advantage.

By writing the Dosage section in straightforward language and highlighting the simplest regimen, we emphasize practicality. Example from Invokana: “The recommended starting dosage... is 100 mg orally once daily, taken before the first meal of the day to improve glycemic control” (^[60]). This not only states the dose but repeats the efficacy goal. It also clearly says “once daily” and “before the first meal”, giving practical cues. For drugs with multiple indications, mention if dosing differs by indication, which can itself highlight precision (e.g. “For diabetes: 50-100 mg; for heart failure: 50 mg” – if such distinctions exist).

In sum, dosage information should accurately communicate the approved regimen and critical administration requirements.

Although we want the Highlights to shine on benefits, the Boxed Warning and Contraindications cannot be ignored – they are often the first things the eye lands on. Optimizing these sections is about succinct communication and not obscuring them:

• Boxed Warning (BBW). If the drug has a Black Box Warning, legally it must appear at the very top of Highlights (^[25]). The content is that of the boxed warning in Section 5, shrunk to about 20 lines. While this is a “negative” part of the label, it can still be written clearly. Summarize the core message in a way that is understandable (e.g. “WARNING: Severe liver injury” or “Life-threatening infections”). Do not bury it in verbiage – the heading “WARNING:” and bold formatting already signal its importance. Immediately after the summary, include the standard line “See full prescribing information for complete boxed warning” (^[25]).

• Contraindications. These are absolute “do not use” situations. Keep them terse and to the point (“Hypersensitivity to any component”; “History of lacrimal calcification,” etc.). Listing them clearly (often bullets) emphasizes who should not get the drug. While not a selling point, a well-written contraindication section can indirectly highlight safety (for instance, showing that pregnancy is only a precaution, not a contraindication, might make a drug more appealing for women of childbearing age).

A key principle from FDA and labeling experts is that serious warnings must be upfront (^[45]) (^[3]). You cannot push negatives to a later page; a prescriber reading HIGHLIGHTS will see them. Therefore, optimization here means clear and concise wording, and yes, including them balanced with the positive Indications. The “value proposition” sense here is trustworthiness – showing that the label does not sweep risks under the rug and that the company is transparently informing doctors.

Following Warnings and Precautions, Highlights includes a concise summary of adverse reactions from the approved labeling. Formatting may improve readability, but the summary must accurately communicate the approved risk information and must not minimize it. Best practices include:

• Frequency listing. Numbering or bulleting adverse events by decreasing incidence or by body system helps readability. For example, list the most frequent ones first with their frequency (e.g. “nausea (11%), headache (10%)…”) if space permits. FDA doesn’t require exact percentages in Highlights, but including “(≥5%)” is customary (^[37]). This transparent data shows the most likely side effects.

• Common versus serious. The most common side effects for chronic drugs are often mild (e.g., headache, GI upset). Including them upfront (with their rates) implicitly suggests that serious AEs are less frequent. After the common list, a brief mention of rare but serious AEs is sometimes included under Warnings instead. This way, the Highlights first informs about side effects the clinician is likely to see.

• Reporting statement. Mandatory FDA reporting language is always included in Adverse Reactions (^[36]). It is verbatim and is usually placed at the bottom of this section (^[61]). While regulatory, its presence reminds prescribers that vigilance is part of safe use.

Formatting can improve readability, but it must not minimize or reframe risk. The adverse-reactions summary should accurately reflect the approved labeling, while clinically significant warnings and precautions remain prominent in their required sections.

The final mandatory safety summaries are Drug Interactions and Use in Specific Populations. These sections should accurately summarize the applicable approved safety information:

• Drug Interactions. Summarize only the most critical interactions (^[39]) (^[38]). For example, state “Strong CYP3A4 inhibitors: avoid coadministration” or “Live vaccines: not recommended”. Keep the wording active and clear (e.g. “Avoid use with” or “Do not administer”). As noted, lengthy lists of example drugs can be counterproductive (^[8]), so use class-based statements. This reassures prescribers that the label addresses interactive risk without implying false completeness. It also demonstrates oversight: e.g. “Interactions with hepatic enzyme inducers/inhibitors have been studied and managed.”

• Use in Specific Populations. This catches pregnancy/lactation, pediatric, geriatric, organ impairment. Under the Pregnancy and Lactation Labeling Rule (PLLR), Highlights should mention the “Pregnancy Risk Summary.” For example, “Pregnancy: May cause fetal harm (see 8.1).” or “Lactation: Risk unknown; discontinue after delivery if used”. We cite 21 CFR here (^[19]). If a drug has no data in a population, state it. For populations where the drug can be used normally, stating “no dose adjustment necessary” is a selling point. If age 65+ has no special risk, saying so can signal that the drug is suitable for elderly patients.

When a product has an approved pediatric indication, stating the age range explicitly can improve clarity. The current INVOKANA label includes glycemic-control use in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus; its cardiovascular and kidney-outcome indications apply to specified adult populations. (^[59])

Overall, when drafting Highlights:

• Lead with the approved information: Present the indication, dosage, limitations of use, and safety information in the required order and with wording supported by the approved labeling. Do not arrange information to make risks appear less important.
• Use headline terms: Bold headings (Boxed Warning, Indication titles, etc.) draw the eye – placing a benefit verb (e.g. “Adjunct to improve…”) immediately after a bullet star is ideal.
• Short actionable statements: Phrases like “Recommended starting dose 10 mg once daily” highlight ease-of-use.
• Classify advantage: A very useful trick is to use the drug class to hint at benefits. For example, “a calcium channel blocker” signals work on hypertension – the indication can then say “treatment of hypertension with or without Benzodiazepines” (just an illustration).
• Substantiate with references: While Highlights text cannot cite literature, the underlying full label includes data tables. Developers should ensure every positive claim in Highlights relates to solid study results in the label, so that label discussions, tables, and references (in the Full PI) back it up. (Regulatory negotiation will remove any unsupported claim (^[18]).)

Table 2 (below) illustrates how different HPI sections can be optimized for value emphasis:

Table 2: Drafting considerations for accurately summarizing approved information in each Highlights section.

Understanding how healthcare providers use the PI can guide highlight-writing strategy. Recent qualitative research offers valuable insights:

• Physician priorities: Interviews with U.S. physicians revealed that Indications and Usage, Dosage and Administration, and Contraindications are the sections they find most critical for their prescribing decisions (^[62]). These are exactly the sections we emphasize for “value.” In contrast, physicians often find overly long sections cumbersome and prefer highlights that get straight to the point. For example, doctors in the study strongly preferred explicit age specifications in Indications and clear food instructions in Dosage (^[8]). They noted confusion when adult dosing was implied rather than stated. This suggests that Highlights should explicitly say “adults,” “pediatric,” etc., and include food-related guidance if relevant (^[8]).

• Clarity of warnings: In one of the interview scenarios, physicians were shown different ways of phrasing warnings (e.g. “contraindicated in renal impairment” vs “avoid use in renal impairment”) (^[63]). They interpreted slight wording differences as differing severity. The consensus was that terms like “contraindicated” (strong prohibition) and “avoid” (strong recommendation) can have different practical meanings. This underscores that word choice matters. For Highlights writers, it’s critical to use regulatory and plain language precisely (e.g. follow FDA’s definitions exactly and be consistent with full label wording). Changing “Contraindicated” to “Not recommended” without approval can confuse readers and violate guidelines.

• Information overload: Physicians in the study cautioned against too much detail in interactions and side effects. They felt that a long list of drug interactions might be misread as exhaustive (^[8]). Similarly, if Highlights gave an overwhelming number of side effects, it might obscure what’s most important. Thus our recommendations to slim these sections to essentials align with clinician desires.

• Trust and tone: Providers stressed they rely on PI for factual, legally-vetted information, not marketing claims. One study summarized: “Sections of the PI that physicians found most useful were those with practical implications for prescribing” (^[62]). Highlights should therefore be transactional in tone – informative, not persuasive. That’s consistent with FDA’s requirement that labels “be informative and accurate and neither promotional in tone nor false or misleading” (^[4]).

In essence, the research confirms that simplicity and relevance win out. A Highlights section overflowing with minutiae will be underused. Instead, by focusing on the precise clinical question (“Is this right for my patient? How do I dose it? What are the big risks?”) and answering it succinctly, the label becomes a useful tool. For example, doctors prefer seeing “with or without food” than digging in the full label (^[8]). Our optimization leverages exactly these preferences: it calls out age, food, and clear yes/no statements where doctors want them.

To illustrate these principles, we consider real and hypothetical Highlights sections. These examples show how language and structure can affect clarity and the accurate communication of approved information.

Case Study 1: A Diabetes Therapy (INVOKANA)

The current FDA-approved INVOKANA Highlights illustrate how a label can present multiple approved uses concisely. INVOKANA is an SGLT2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus; it also has specified cardiovascular and kidney-outcome indications for defined adult populations. The Highlights list a 100 mg once-daily recommended starting dosage before the first meal of the day for adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, with an increase to 300 mg once daily only for eligible patients who need additional glycemic control. The product is supplied as 100 mg and 300 mg tablets.

The current label does not contain a boxed warning. Its Highlights instead summarize clinically significant warnings and precautions, including ketoacidosis, lower-limb amputation, volume depletion, serious urinary tract infections, hypoglycemia with concomitant insulin or insulin secretagogues, Fournier’s gangrene, genital mycotic infections, hypersensitivity reactions, and bone fracture. This example underscores a core drafting principle: the approved benefits, dosing, and safety information must be accurately reflected together, without importing content from another product's label. (^[64])

Case Study 2: Novel Oncology Agent (Hypothetical)

Imagine a new cancer drug, OncoX. Its clinical trials showed a median survival improvement of 4 months over chemotherapy in metastatic disease. The INDICATION is: “Treatment of metastatic carcinoma of X in patients with progression after prior therapy.”

The Highlights indication should reproduce the hypothetical product’s FDA-approved indication in concise, non-promotional language. A survival claim may appear only if it is itself part of the approved indication or other approved labeling and is presented with the necessary population, endpoint, and limitation context. Do not use an unresolved citation placeholder or recast a trial result as an indication claim.

Warnings and precautions should likewise summarize the approved safety language and cross-reference the relevant Full Prescribing Information sections. This hypothetical illustrates that an indication cannot be “tuned” to imply a patient outcome that is not stated in the approved labeling.

Case Study 3: Generic-Drug Labeling (Conceptual)

Consider two drugs, HeartMed (brand) and HeartGen (generic) for hypertension. HeartMed’s Highlights might say: “as monotherapy or adjunct to reduce blood pressure” and “once-daily dosing.” For an ANDA generic, labeling generally must be the same as the reference listed drug (RLD) labeling, but permissible differences can include omission of an indication protected by patent or exclusivity and certain manufacturer-specific or FDA-guideline-related changes. Thus, the labels will often be similar, but they need not always copy every indication exactly. (^[65])

If HeartMed could claim in its Highlights (per FDA allowance) “head-to-head trials have shown greater BP reduction vs DrugZ (^[18]),” the wording must be evidence-based and approved. An example claim might be: “HeartMed demonstrated on average a 15% greater systolic BP reduction versus comparator”. However, if FDA removal or interpretation says “NO comparative claims without evidence”, it must be withheld. The good labeling way: focus on what HeartMed is, not what it is not. For instance “the pharmacologic class (ACE inhibitor) and dosing regimen identical to standard therapy” is allowed context but not an advantage per se.

This case illustrates that ANDA labeling generally must be the same as the reference listed drug labeling, subject to applicable permissible differences. Highlights for either a brand or generic product should state approved information accurately and should not use promotional comparative framing. (^[65]; FDA labeling FAQ)

Though the Highlights section is not typically a venue for raw data, a few published sources shed light on labeling and highlight usage:

• Evidence limitations: The sources reviewed support the purpose and required structure of Highlights, but they do not establish a quantitative increase in clinicians’ ability to locate key information. FDA describes Highlights as a concise summary of crucial prescribing information needed for safe and effective use. (^[56])

• PI Use Metrics: The National Library of Medicine’s DailyMed platform (dailymed.nlm.nih.gov) now hosts over 155,000 labeling documents submitted to the FDA by manufacturers (^[14]) (^[66]). Congress has noted that information in Highlights is widely accessed online by providers via DailyMed (which publishes Highlights with search functions). The FDA has also launched the FDALabel full-text search tool, which allows section-specific searching across all approved labels – searching specific sections like Boxed Warning or Adverse Reactions yields significantly more relevant results than full-text search (^[15]). Additionally, researchers have developed AI-powered tools such as AskFDALabel, which leverages large language models to enhance annotation, profiling, and classification of drug adverse events from labeling documents (^[67]). These digital tools suggest broad and growing reliance on Highlights in the digital age.

• Physician behavior: A cited survey (the qualitative study discussed above) indicated that a random sample of 70 U.S. physicians regularly consult the PI for prescribing information (^[68]). Among content features tested, clear dosage instructions and indications with explicit terms significantly improved understanding – though the study reported these findings qualitatively. (No large-scale quantitative survey of reading times exists publicly, but we infer from FDA and AMA activities that accessible highlights improve prescribing accuracy.)

• Writing & readability: The FDA and industry emphasize clarity. One guideline (“Evidence-Based Design of Prescription Medication Information”, 2018) recommends plain language and organized structures (though it focused on patient leaflets) (^[69]). The same principles apply to professional labeling.

• Adoption of PLR: A 2011 commentary noted that even after PLR, many labels were still too dense, and highlighted the ongoing need to improve package inserts to help busy prescribers (^[70]). Research like this underscores why optimization is iterative: compliance doesn’t guarantee clarity.

In sum, while concrete statistics on Highlights efficacy are limited, the available evidence consistently supports our focus on clarity, brevity, and balance. Regulatory shifts (PLR, Pregnancy Labeling Rule, the Prescription Information Modernization Act of 2025 (^[71]), and ongoing e-label reforms) all aim to make crucial information easier to find. The digitalization of labeling processes – including XML-based structured labeling, integrated artwork and document management, and audit-trail automation – is transforming what was historically a manual, document-driven process into an integrated, automated workflow aligned with FDA 21 CFR Part 11 data integrity principles (^[72]). Companies that proactively optimize their Highlights are turning regulatory necessities into an asset for prescribers.

Optimizing HPI has implications across regulatory affairs, medical communications, and patient safety:

• Regulatory strategy: A strong Highlights section can streamline FDA review. Clear, concise Highlights reduce back-and-forth over labeling semantics. Early consideration of “value languages” (with regulatory negotiation) may yield insert language that subtly underscores benefits yet passes muster. For example, FDA’s 2018 draft guidance on product title stressed consistency in naming (^[73]) – our approach similarly emphasizes consistency between Highlights and clinical evidence.

• Interdisciplinary coordination: Crafting exceptional Highlights requires collaboration between regulatory, clinical, safety, and communications teams. Regulatory experts ensure CFR compliance; medical writers shape language for clarity; clinical scientists suggest which trial results to highlight. All claims must trace to evidence in clinical reports. A “two-click” rule (every statement traceable to the dossier) has been recommended in labeling SOPs (^[74]).

• Technological evolution and AI: The future is already seeing Highlights enhanced by technology. Structured Product Labeling (SPL) is the electronic format used to submit and distribute labeling; electronic SPL can support hyperlinks between Highlights references and the Full Prescribing Information (^[56]). In January 2025, the FDA issued landmark draft guidance on "Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products," establishing a seven-step, risk-based credibility assessment framework for AI models used in drug development and regulatory submissions (^[75]). By June 2025, the FDA deployed an agency-wide large language model assistant called "Elsa" to support internal scientific review, capable of performing rapid label comparisons, assisting with clinical-protocol review, and summarizing adverse events. In electronic labels, we could incorporate data toggles or expandable sections (though printed Highlights remain static). Additionally, AI-powered tools are increasingly being used to analyze labeling for readability, flag inconsistencies, and identify missing information before submission.

• Patient engagement and electronic distribution: Although USPI is for professionals, Highlights can influence patient access. Many patients retrieve drug labels online (DailyMed, institutional databases). A well-written Highlights could indirectly improve patient understanding when they encounter it (though it’s technical). More directly, clear Highlights dovetail with clearer patient Medication Guides and counseling materials, reinforcing consistent messaging. Notably, the bipartisan Prescription Information Modernization Act – reintroduced in the 119th Congress in 2025 (^[71]) – would allow the FDA to finalize a proposed rule permitting drug manufacturers to distribute prescribing information electronically rather than on printed paper. If enacted, this legislation would require the Secretary of Health and Human Services to issue final implementing regulations within one year, while preserving healthcare professionals’ ability to request paper copies. This shift would improve patient safety by ensuring prescribers always access the most current labeling and reduce environmental waste from paper inserts.

• Global perspective: Sponsors developing multi-region strategies should note differences. E.U. SmPCs have a “Summary of Product Characteristics” but no separate “Highlights” section exactly like the U.S. model. However, the principle of an accessible summary is shared (e.g. PILs in EU). A harmonized approach—focusing on clarity and balance—benefits all markets, but content may be adapted to local regulations (e.g. EMA doesn’t require an “Initial EU Approval” line). As cross-border data sharing increases, well-crafted U.S. Highlights can serve as a template for other jurisdictions.

• Generic drug labeling: FDA’s January 2024 final guidance, which finalized a January 2022 draft, addresses how ANDA applicants and holders should update labeling after revisions to the approved labeling of the reference listed drug (RLD). It explains how to identify RLD updates and submit conforming amendments or supplements. The guidance does not establish a generic-drug Changes Being Effected pathway, and labeling updates after withdrawal of an RLD for reasons other than safety or effectiveness are outside its scope; FDA directs applicants to section 503D of the FD&C Act and the relevant draft guidance. (^[65])

• Ongoing research: The dynamics of prescribing and labeling should be monitored. Clinicians increasingly use smartphone apps, electronic health record integrations, and AI-powered clinical decision support tools with interactive labeling. Highlights could evolve to incorporate clickable definitions, linked clinical trial data, or dynamic risk-benefit visualizations. Real-world prescribing data and post-market surveillance signals may eventually be integrated into labeling updates more rapidly, driven by advances in real-world evidence (RWE) analytics.

The Highlights section of the USPI is a regulated summary of a drug’s indications, dosing, and safety information. It should help healthcare professionals locate crucial prescribing information quickly by presenting the approved label accurately, concisely, and without promotional framing.

Our comprehensive review of guidelines, research, and examples shows that doing Highlights well is an art and science. It requires understanding the regulations (21 CFR 201.57) down to verbatim statements (^[17]) (^[19]), listening to physicians’ needs (explicit age and food info, straightforward dosage instructions) (^[8]), and applying clear writing techniques (bullets, headings, consistent terms) (^[5]) (^[6]). The reward is higher: labeling that is compliant, informative, and user-friendly.

The future is already bringing more emphasis on the Highlights as technology and regulatory focus evolve. The 2025 reintroduction of the Prescription Information Modernization Act (^[71]), the FDA's AI credibility framework for regulatory submissions (^[76]), current generic-drug labeling requirements, and the growing adoption of SPL-based electronic labeling all signal a transformation in how prescribing information reaches clinicians. The core principles remain: present the approved information accurately, concisely, and without promotional framing so healthcare professionals can locate the information needed for safe and effective use.

References: This report draws on federal regulations and FDA guidance (^[17]) (^[2]), published regulatory analyses (^[3]) (^[7]), physician survey data (^[8]) (^[4]), and real-world labeling examples (^[9]). All claims and recommendations above are grounded in these authoritative sources.